Earnings Call Summary | OncoCyte(OCX.US) Q1 2024 Earnings Conference
Earnings Call Summary | OncoCyte(OCX.US) Q1 2024 Earnings Conference
The following is a summary of the OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript:
以下是OncoCyte Corporation（OCX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
OncoCyte reported a net revenue of $176,000 in Q1 2024, marking a 41% decrease from Q1 2023.
The company's cash reserves declined by $3.9 million in Q1 2024, leaving $5.6 million on the balance sheet.
GAAP net loss from continuing operations was reported to be $9.1 million, in comparison to a net income of $6 million in Q1 2023.
The company managed to raise $15.8 million in a recent private placement.
OncoCyte報告稱，2024年第一季度淨收入爲17.6萬美元，比2023年第一季度下降了41％。
該公司的現金儲備在2024年第一季度減少了390萬美元，資產負債表上留下了560萬美元。
據報道，來自持續經營業務的GAAP淨虧損爲910萬美元，而2023年第一季度的淨收入爲600萬美元。
該公司在最近的一次私募中成功籌集了1,580萬美元。
Business Progress:
業務進展：
OncoCyte is in the initial phases of commercialisation of its GraftAssure product and has initiated a partnership with Bio-Rad Laboratories to increase its influence in reputed academic centers.
Plans are underway to introduce the VitaGraft Kidney IVD to the market, a proprietary technology that could detect organ rejection in transplant patients much earlier than current methods.
The company is actively working on introducing its products in the oncology field, specifically DetermaCNI and DetermaIO.
Significant progress has been made in establishing relationships with potential beta sites for product launches, particularly in Germany. Interest has also been generated in the U.S. and Asia.
Future recruitments have been planned by the end of the quarter in collaboration with Bio-Rad team to strengthen the business presence by Q4.
OncoCyte的GraftAssure產品正處於商業化的初始階段，並已開始與Bio-Rad實驗室建立合作伙伴關係，以增加其在知名學術中心的影響力。
正在計劃將VitaGraft腎臟體外診斷技術推向市場，這是一項專有技術，可以比目前的方法更早地檢測移植患者的器官排斥反應。
該公司正在積極努力在腫瘤學領域推出其產品，特別是DetermacNI和DeterMAIO。
在與潛在的產品發佈測試網站建立關係方面取得了重大進展，特別是在德國。美國和亞洲也產生了興趣。
與Bio-Rad團隊合作，計劃在本季度末之前進行未來的招聘，以在第四季度之前加強業務影響力。
More details: OncoCyte IR
更多詳情： oncoCyte IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。